## News

### [‘Decoy’ Protein Offers New Treatment Approach For Covid-19 – (Forbes.com)](/content/decoy-protein-offers-new-treatment-approach-for-covid-19-forbes-com/index.html)

February 3, 2022

Recently William Haseltine wrote an excellent article on Forbes regarding ACE2 research and the development of therapeutics for SARS-Cov2. The article includes a link to research performed by Cyrus scientists Erik Procko …

### [Cyrus Biotechnology CEO Lucas Nivon featured in Fierce Biotech Webinar](/content/cyrus-biotechnology-ceo-lucas-nivon-featured-in-fierce-biotech-webinar/index.html)

January 28, 2022

Date:  Thursday, February 3, 2022  
Time:  2pm ET / 11am PT  
Duration:  1 Hour  
Sign up here to go to the webinar Improving the discovery of novel drugs with artificial intelligence Last year, Toronto-based Deep …

### [Cyrus ACE2.v2.4 candidate’s in vivo activity and prevention of lung damage demonstrated by University of Illinois College of Medicine department of Pharmacology – (Nature.com)](/content/cyrus-ace2-v2-4-candidates-in-vivo-activity-and-prevention-of-lung-damage-demonstrated-by-university-of-illinois-college-of-medicine-department-of-pharmacology/index.html)

January 26, 2022

[https://www.nature.com/articles/s41589-021-00965-6](https://www.nature.com/articles/s41589-021-00965-6)

### [Cyrus Biotechnology’s COVID therapeutic lead, ACE2.v2.4, strongly binds and neutralizes SARS-CoV-2 omicron variant potentially providing long term protection](/content/cyrus-biotechnologys-covid-therapeutic-lead-ace2-v2-4-strongly-binds-and-neutralizes-sars-cov-2-omicron-variant-potentially-providing-long-term-protection/index.html)

December 27, 2021

SEATTLE, WA – (BUSINESS WIRE) – Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary platform for biologics discovery that combines software, AI and large-scale parallel protein screening, today announced that …

### [Cyrus Biotechnology Announces $18M Financing and Acquisition of Orthogonal Biologics to Form an Integrated Software-Driven Pre-Clinical-Stage Drug Discovery Firm – (Businesswire)](/content/cyrus-biotechnology-announces-18m-financing-and-acquisition-of-orthogonal-biologics-to-form-an-integrated-software-driven-pre-clinical-stage-drug-discovery-firm/index.html)

December 6, 2021

SEATTLE, WA December 6, 2021 — Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary software platform for biologics discovery, today announced the closing of a $18M Series B financing and …

### [Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins](/content/selecta-biosciences-and-cyrus-biotechnology-enter-collaboration-to-create-novel-engineered-therapeutic-proteins/index.html)

September 9, 2021

– First collaboration program, leveraging Cyrus’ de novo computational approach to create proprietary IL-2 protein agonist targeting autoimmune and other deleterious immune conditions- -Preclinical data demonstrate synergistic activity of ImmTOR in combination …